SYBLEU (SYBE) Stock Price

SYBLEU Price

NYSE·CLOSED
0.05
​
Market closed

Over the last 2 years SYBLEU grew revenue by 68.9% annually, reaching 11,700.00 USD. For SYBLEU, the net margin of -1,541.0% is up versus -2,485.4% a few years ago.

SYBLEU stock price

Access this data via the Eulerpool API

SYBLEU business model & stock analysis

SYBLEU, Inc. intends to engage in the development of regenerative medical applications. The company is headquartered in Bronx, New York. The company went IPO on 2023-03-09. The firm is focused on developing therapies for human and animal health, medical devices, and clinical diagnostics. The firm is also developing drugs for treating cancer in companion animals and examining the role of artificial intelligence and machine learning in clinical diagnostics. The company is also involved in the development of disposable medical devices. The company has completed Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.

Frequently asked questions about SYBLEU

Converted at the current exchange rate, the SYBLEU share trades at 0.05 EUR (0.05 USD).

The revenue cannot currently be calculated for SYBLEU.

The profit cannot currently be calculated for SYBLEU.

The P/E ratio cannot be calculated for SYBLEU at the moment.

The P/S cannot be calculated for SYBLEU currently.

The Eulerpool Quality Score for SYBLEU is 3/10.

The ISIN of SYBLEU is US87114K1051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of SYBLEU is SYBE. The ticker symbol is used to trade SYBLEU shares on the stock exchange.

Fair ValueTerminal
0.05 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website
Currency
USD
Initial public offering
Mar 9, 2023
ISIN
US87114K1051
Cusip
87114K105
Market capitalization
5.47 M USDMicro Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-142.53 %
Gross Margin
—
EBIT Margin
-1,275.21 %
Net Margin
-1,541.03 %
EPS (Earnings Per Share)
-0.02 USD
Net Debt / EBIT
-3.17
Debt/Equity
-1.36
Last updated Oct 5, 2026, 10:41 AM

SYBLEU Peer Group

SYBLEU FIGI

SYBE:US · BBG00X71LG35SYBE:PQ · BBG01FSR8RP0SYBE:UV · BBG01FSR8RQ9

All fundamentals and in-depth analysis of SYBLEU

Our stock analysis for SYBLEU stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SYBLEU. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.